Alaunos Therapeutics, Inc. (TCRT) Return on equity 2018–2025
Alaunos Therapeutics, Inc. (TCRT) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-194.0%FY2025 · since FY2018: -62.1% → -194.0%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -194.0% | +32.8 pp |
| FY2024 | -226.8% | -152.6 pp |
| FY2023 | -74.2% | +23.7 pp |
| FY2022 | -97.9% | +37.8 pp |
| FY2021 | -135.6% | -71.1 pp |
| FY2020 | -64.5% | — |
| FY2018 | -62.1% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More TCRT financial trends
TCRT RevenueTCRT Net incomeTCRT Net marginTCRT Gross profitTCRT Gross marginTCRT Operating incomeTCRT Operating marginTCRT Operating cash flowTCRT Free cash flowTCRT Capital expendituresTCRT Stock buybacksTCRT Dividends paidTCRT Total assetsTCRT Total liabilitiesTCRT Shareholders’ equityTCRT overview →